Merck & Co., Inc.’s Keytruda and Bristol Myers Squibb Company’s Opdivo might be the only Medicare Part B drugs that will be subject to negotiated prices in 2028, the first year that Part B drugs will be eligible, according to an analysis by Sean Dickson, West Health Policy Center, and Immaculada Hernandez, University of California, San Diego.
Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year
In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.
More from Market Access
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
Experts say PBMs should become familiar with transparency rules and prepare to release data, although more legal wrangling could occur.
• By
Optum Rx, one of the largest PBMs in the US, declared it was the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
Health technology assessment body NICE said it has taken on feedback about the implications of allowing higher cost-effectiveness thresholds for some medicines after senior health economists offered diverging views on its methods.
More from Pink Sheet
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
The Brazilian medicines regulator will also offer more clarity on the requirements for radiopharmaceuticals that are exempt from registration.
• By
South Korea announces planned revisions to a government scheme to designate "innovative" biopharma companies amid allegations of "discrimination" against foreign firms.